Drug Profile
T 786
Latest Information Update: 29 Mar 2001
Price :
$50
*
At a glance
- Originator Trimeris
- Class Antivirals
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 29 Mar 2001 Discontinued-Preclinical for Respiratory syncytial virus infections in USA (Unknown route)
- 22 Dec 1998 New profile
- 22 Dec 1998 Preclinical development for Respiratory syncytial virus infections in USA (Unknown route)